Cutler Group LP Vaxcyte, Inc. Call Options Transaction History

Cutler Group LP

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 Apr 19, 2024	BUY	$59.79 - $81.05 $89,685 - $121,575	1,500 Added 30.0%	6,500 $4,000
Q4 2023 Jan 18, 2024	BUY	$45.35 - $63.41 $226,750 - $317,050	5,000 New	5,000 $78,000
Q1 2023 May 01, 2023	SELL	$36.27 - $47.2 $126,945 - $165,200	-3,500 Reduced 53.85%	3,000 $0
Q4 2022 Feb 07, 2023	BUY	$20.58 - $47.95 $133,770 - $311,675	6,500 New	6,500 $107,000

357

123M

775K

433K

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $5.26B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.